Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01093508 · ClinicalTrials.gov registry record · Phase 1
Single-dose Safety Study of APD916 in Healthy Volunteers
A Phase 1 study of Narcolepsy With or Without Cataplexy, sponsored by Arena Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT01093508 is a Phase 1 study of Narcolepsy With or Without Cataplexy that has completed, run by Arena Pharmaceuticals. The registered enrollment target is 72 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01093508, a Phase 1 study of Narcolepsy With or Without Cataplexy, has completed, sponsored by Arena Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
The APD916-001 study is designed primarily to evaluate the safety and tolerability of APD916 when administered as a single dose
Conditions Studied
Interventions
- DRUG APD916
Study Locations (1)
Ohio
- Community Research - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01093508
The ClinicalTrials.gov registry entry for NCT01093508 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arena Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Narcolepsy With or Without Cataplexy appearing as the primary indexed condition, and to 1 intervention - of which APD916 is the first listed.
NCT01093508 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT01093508 about?
NCT01093508 is a clinical study titled "Single-dose Safety Study of APD916 in Healthy Volunteers". The APD916-001 study is designed primarily to evaluate the safety and tolerability of APD916 when administered as a single dose
What is the current status of trial NCT01093508?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2010-03. Estimated completion is 2010-07.
What conditions does trial NCT01093508 study?
This clinical trial studies the following conditions: Narcolepsy With or Without Cataplexy.
What interventions are being tested in trial NCT01093508?
The interventions under investigation include: APD916 (DRUG).
Who is sponsoring clinical trial NCT01093508?
This trial is sponsored by Arena Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01093508 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.